Study Objective: To assess the potential clinical impact of thrombolytic therapy for acute myocardial infarction by determining true-positive and false-positive rates of criteria for eligibility among emergency room patients with acute chest pain.

Design: Prospective multicenter cohort study.

Setting: Emergency rooms of three university and four community hospitals.

Patients: Emergency room patients (7734) with acute chest pain.

Measurements and Main Results: Only 261 (23%) of 1118 patients with acute myocardial infarctions were 75 years of age or younger, presented within 4 hours of the onset of pain, and had emergency room electrocardiograms showing probable acute myocardial infarction; 60 (0.9%) of the 6616 patients without infarction also met these criteria (positive predictive value, 261/321 = 81%; CI, 77% to 86%). The positive predictive value could increase to about 88% (CI, 82% to 93%) if eligibility were based on the official hospital electrocardiogram reading.

Conclusions: Because experience from published studies suggests that about one third of patients who meet these three eligibility criteria have other contraindications to thrombolysis, we estimate that about 15% of patients with acute myocardial infarction would meet the criteria for eligibility for thrombolysis that have been used in clinical trials at the time of emergency room presentation. Further, for every eight patients with true-positive results who are treated, one to two patients with false-positive results may also be treated if decisions are based on the interpretation of a single electrocardiogram.


  • 1. . Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987;2:871-4. MedlineGoogle Scholar
  • 2. Simoons MSerruys P, and van den Brand M. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol. 1986;7:717-28. CrossrefMedlineGoogle Scholar
  • 3. Kennedy JMartin G, and Davis K. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial. Circulation. 1988;77:345-52. CrossrefMedlineGoogle Scholar
  • 4. . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-60. MedlineGoogle Scholar
  • 5. Anderson JRothbard R, and Hackworthy R. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J Am Coll Cardiol. 1988;11:1153-63. CrossrefMedlineGoogle Scholar
  • 6. . A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.): mortality, morbidity, and infarct size at 21 days. N Engl J. Med. 1986;314:1465-71. CrossrefMedlineGoogle Scholar
  • 7. Laffel GFineberg H, and Braunwald E. A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. J Am Coll Cardiol. 1987:10:79B-90B. CrossrefMedlineGoogle Scholar
  • 8. Hlatky MCotugno HO'Connor CMark DPryor D, and Califf R. Adoption of thrombolytic therapy in the management of acute myocardial infarction. Am J Cardiol. 1988;61:510-4. CrossrefMedlineGoogle Scholar
  • 9. . 1987 Heart Facts. Dallas: American Heart Association; 1987. Google Scholar
  • 10. Goldman LCook E, and Brand D. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med. 1988;318:797-803. CrossrefMedlineGoogle Scholar
  • 11. Lee TRouan G, and Weisberg M. Clinical characteristics and natural history of patients with acute myocardial infarction sent home from the emergency room. Am J Cardiol. 1987;60:219-24. CrossrefMedlineGoogle Scholar
  • 12. Lee TRouan G, and Weisberg M. Sensitivity of routine clinical criteria for diagnosing myocardial infarction within 24 hours of hospitalization. Ann Intern Med. 1987;106:181-6. LinkGoogle Scholar
  • 13. Beamer ALee T, and Cook E. Diagnostic implications for myocardial ischemia of the circadian variation of the onset of chest pain. Am J Cardiol. 1987;60:998-1002. CrossrefMedlineGoogle Scholar
  • 14. Solomon CLee T, and Cook E. Comparison of clinical presentation of acute myocardial infarction in patients older than 65 years of age to younger patients: the Multicenter Chest Pain Study experience. Am J Cardiol. 1989;63:772-6. CrossrefMedlineGoogle Scholar
  • 15. Topol ECaliff RKereiakes D, and George B. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. J Am Coll Cardiol. 1987;10:65B-74B. CrossrefMedlineGoogle Scholar
  • 16. Passamani EHodges M, and Herman M. The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1987;10:51B-64B. CrossrefMedlineGoogle Scholar
  • 17. Murray NLyons JLayton C, and Balcon R. What proportion of patients with myocardial infarction are suitable for thrombolysis? Br Heart J. 1987;57:144-7. CrossrefMedlineGoogle Scholar
  • 18. Jagger JMurray RDavies MLittler W, and Flint E. Eligibility for thrombolytic therapy in acute myocardial infarction. Lancet. 1987;1:34-5. CrossrefMedlineGoogle Scholar
  • 19. Doorey AMichelson EWeber F, and Dreifus L. Thrombolytic therapy of acute myocardial infarction: emerging challenges of implementation. J Am Coll Cardiol. 1987;10:1357-60. CrossrefMedlineGoogle Scholar
  • 20. Gotoh KMinamino T, and Katoh O. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation. 1988;77:526-34. CrossrefMedlineGoogle Scholar
  • 21. Cairns JGent M, and Singer J. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985;313:1369-75. CrossrefMedlineGoogle Scholar
  • 22. Telford A and Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1981;1:1225-8. CrossrefMedlineGoogle Scholar
  • 23. Nicklas JTopol E, and Kander N. Randomized, double-blind,placebo-controlled trial of tissue plasminogen activator in unstable angina. J Am Coll Cardiol. 1989;13:434-41. CrossrefMedlineGoogle Scholar
  • 24. Ambrose JHjemdahl-Monsen C, and Borrico S. Quantitative and qualitative effects of intracoronary streptokinase in unstable angina and non-Q wave infarction. J Am Coll Cardiol. 1987;9:1156-65. CrossrefMedlineGoogle Scholar
  • 25. Gold HJohns J, and Leinbach R. A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris. Circulation. 1987;75:1192-9. CrossrefMedlineGoogle Scholar
  • 26. . Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med. 1989;320:618-27. CrossrefMedlineGoogle Scholar
  • 27. Koster R and Dunning A. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. N Engl J Med. 1985;313:1105-10. CrossrefMedlineGoogle Scholar

This content is PDF only. To continue reading please click on the PDF icon.